Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000950170-25-072042·Dyne Therapeutics, Inc.
Schedule 13G ownership disclosure
Dyne Therapeutics Inc
Common Stock, par value $0.0001 · CUSIP: 26818M108
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ForDyne B.V.
Shares: 5,400,545 · Class: 4.8%
- Forbion Capital Fund IV Cooperatief U.A.
Shares: 4,036,476 · Class: 3.6%
- Forbion IV Management B.V.
Shares: 4,036,476 · Class: 3.6%
- Forbion Growth Opportunities Fund II Cooperatief U.A.
Shares: 1,426,370 · Class: 1.3%
- Forbion Growth II Management B.V.
Shares: 1,426,370 · Class: 1.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-072042
- Form type
- SCHEDULE 13G/A
- Filer
- Dyne Therapeutics, Inc.
- CIK
- CIK 1818794
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership